|
|
News Breaks | | | | December 13, 2012 | | 07:36 EDT |  | NBY | NovaBay provides outlook for FY13
Dr. Ron Najafi, chairman and CEO, said, "2012 was an exciting year for NovaBay. As a result of the hard work from our talented employees and partners, all three of our Aganocide programs, in ophthalmology, dermatology, and urology, are currently in Phase 2 clinical trials. Data is expected from all of these trials in 2013. We plan to use our recent $7M financing to accelerate and expand these clinical trials," Dr. Najafi continued. "For example, we anticipate that these funds will allow us to speed enrollment of patients with additional sites in our global Phase 2b study for adenoviral conjunctivitis. Additionally, we intend to use proceeds from this financing to conduct a Phase 2 study of NVC-422 in bacterial conjunctivitis. We believe that having one product to treat both bacterial and viral conjunctivitis will place NovaBay in a leading position in the market. NVC-422 has the potential to be the conjunctivitis prescription, without need for a test to determine if a patient has the bacterial or the viral form of the disease." | |
|
News For NBY From The Last 14 Days Check below for free stories on NBY the last two weeks. |
|
|
| There are no results for NBY |
|
|
|
|
|
|
